Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Survival Benefits From Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma and Microvascular Invasion After Curative Hepatectomy.

Mu-Gen Dai,Si-Yu Liu,Wen-Feng Lu,Lei Liang,Bin Ye

Clinical Medicine Insights. Oncology（2023）

Cited 1|Views0
No score
Abstract
Postoperative adjuvant targeted therapy can improve the long-term prognosis of patients with HCC and MVI. Therefore, in clinical practice, oral lenvatinib should be recommended for patients with HCC and MVI to decrease tumor recurrence and improve long-term survival.
More
Translated text
Key words
Hepatocellular carcinoma, adjuvant therapy, lenvatinib, recurrence, overall survival
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined